When former President Joe Biden disclosed a Stage 4 prostate cancer diagnosis in May 2025, the public conversation focused on a single fact: his last PSA test had been in 2014. The clinical debate over that gap is real, but it is not the question that matters most to hospitals, health systems, and the lawyers who defend their reimbursement. The more useful question for providers is quieter and more consequential. Why was a routine blood test absent from a decade of care, and who decides whether that test gets paid for when a provider does order it?

The answer runs through a federal advisory panel, a 2010 statute, a 2025 Supreme Court decision, and a coding distinction that quietly drives denials. For providers, the prostate-specific antigen test is a useful case study in how a clinical recommendation becomes a payment rule, and where that rule leaves room for disputes.

A letter grade is a coverage determinant, not just clinical advice

The U.S. Preventive Services Task Force assigns each screening service a letter grade reflecting the strength of the evidence behind it. Most clinicians read those grades as guidance. Revenue cycle teams and payers read them as something closer to law.

Section 2713 of the Public Health Service Act, added by the Affordable Care Act, requires most private health plans, those not grandfathered under the law, to cover services the USPSTF rates A or B with no cost-sharing to the patient. A grade of C or D carries no such mandate. The grade, in other words, sorts a service into one of two financial worlds: first-dollar coverage, meaning the patient pays nothing out of pocket, on one side, and payer discretion on the other.

PSA screening falls on the discretionary side. The Task Force rates it C for men ages 55 to 69, meaning the decision should be individualized, and D for men 70 and older, meaning it recommends against routine screening. Because neither grade reaches the A or B threshold, PSA screening is not a federally mandated no-cost preventive service. Whether and how it is covered depends on the payer, the plan, the patient’s age, and state law rather than on a single national rule.

This is the structural fact behind the Biden anecdote. A test can be clinically reasonable for a given man and still sit outside the coverage mandate that guarantees payment without friction. For providers, that gap is where denials, patient balance-billing surprises, and appeals live.

Braidwood did not settle the question, it relocated it

For more than a year, the entire architecture of USPSTF-driven coverage was in legal doubt. In Kennedy v. Braidwood Management, Inc., plaintiffs argued that the Task Force was unconstitutionally structured, which would have unwound the A and B coverage mandate nationwide.

On June 27, 2025, the Supreme Court rejected that challenge in a 6 to 3 decision written by Justice Kavanaugh, and the preventive services mandate remains in force. The reasoning matters more to providers than the result. The Court upheld the Task Force precisely because it answers to a political appointee. The Secretary of Health and Human Services can remove its members at will and can review and block their recommendations before those recommendations take effect. That supervision is what let the Court classify the members as inferior officers, meaning lower-level officials who do not require Senate confirmation.

The implication is the part to watch. Because the Court tied the mandate’s survival to the Secretary’s control, the executive branch now has direct authority over which recommendations stand. A future Secretary could reshape Task Force membership or send recommendations back for reconsideration. A service could move into or out of the no-cost-sharing category through political and administrative channels rather than purely scientific ones. Related challenges involving other recommending bodies were sent back to the lower courts and remain unresolved.

For a reimbursement practice, the takeaway is practical. USPSTF actions are no longer just clinical news. They are leading indicators of coverage change, and the panel’s outputs now sit closer to executive discretion than they did before Braidwood.

Medicare follows a different road entirely

The PSA test illustrates a point that often gets lost in coverage analysis: the ACA preventive mandate is not the only pathway, and a service excluded from one can be guaranteed by another.

Medicare covers an annual PSA screening test for male beneficiaries beginning at age 50, and the beneficiary pays nothing for the blood test itself when the provider accepts assignment, with the Part B deductible not applying to that test. That coverage does not flow from the USPSTF grade. It exists by separate statutory authority specific to Medicare. The result is a coverage paradox worth noting: the same test the Task Force recommends against for men over 70 is a covered annual benefit for the Medicare population, which is overwhelmingly over 65.

The associated services do not share that generosity. A digital rectal exam carries the standard 20 percent coinsurance after the Part B deductible. Downstream diagnostics such as imaging and biopsy are covered when medically necessary but carry their own cost-sharing and their own medical-necessity scrutiny. Many states separately mandate private coverage of PSA screening, often extending it to younger high-risk men, which adds another layer that varies by jurisdiction.

The screening versus diagnostic line is where claims are won or lost

The single most useful distinction in this area is one the headlines never mention. A PSA test ordered with no symptoms, as routine screening, is adjudicated differently than a PSA test ordered to evaluate symptoms or to follow a known abnormality. The first is a preventive screening service. The second is a diagnostic test.

That distinction drives coding, coverage, and patient cost-sharing, and it is a frequent denial flashpoint. A claim coded as screening when the clinical record supports a diagnostic indication, or the reverse, invites denial, recoupment, or a cost-sharing dispute with the patient. The documentation in the chart, not the label on the claim, ultimately controls how the service should be characterized. When a denial turns on that characterization, the medical record is the evidence that resolves it.

This is the everyday version of the Biden story. The interesting reimbursement questions are rarely about whether a test is good medicine. They are about how the encounter was documented, how the claim was coded, and which coverage pathway the payer applied.

The exposure does not end when the claim is paid

The reimbursement consequences extend well past initial payment. When a payer or auditor later concludes that a service was characterized as screening when the record supported a diagnostic indication, or the reverse, the provider can face recoupment demands. Where auditors apply statistical sampling, those demands often arrive as extrapolated overpayment findings that turn a handful of reviewed charts into a six- or seven-figure liability. If the coding pattern appears systemic rather than isolated, it can also raise False Claims Act exposure. That exposure turns not on the coding error itself but on whether the provider submitted claims with knowledge of, or reckless disregard for, their accuracy, the subjective scienter standard the Supreme Court clarified in Schutte v. SuperValu. The screening versus diagnostic distinction therefore affects not only coverage and payment but audit defense and compliance, which places it squarely on the desks of compliance officers, general counsel, and executives, not revenue cycle alone.

What providers and their counsel should take from this

A high-profile diagnosis is a reminder to revisit the unglamorous mechanics that determine payment. Several points follow from the analysis above.

First, treat USPSTF grades as coverage signals, not just clinical ones. A change in a grade can move a service across the no-cost-sharing line, with direct revenue and patient-liability consequences.

Second, watch the post-Braidwood environment. The mandate stands, but the Court confirmed executive authority over the panel, so coverage that feels settled may prove contingent. Monitoring Task Force activity is now part of prudent revenue cycle planning.

Third, mind the screening versus diagnostic distinction at the point of documentation, not at the point of appeal. Accurate, contemporaneous clinical documentation is the strongest defense against a coverage denial, because it establishes which pathway applies.

Fourth, map the overlapping coverage sources. Federal mandate, Medicare statute, and state law do not align neatly, and the gaps between them are where balance-billing complaints and payer disputes arise.

The clinical world debates whether the test should have been done. The reimbursement world asks a different question: once it is done, under what authority is it covered, how should it be documented and coded, and what happens when a payer says no. That second question is the one that lands on a provider’s revenue cycle and, often enough, on a litigator’s desk.

A screening guideline is written for populations. A claim is adjudicated one patient at a time. The distance between those two facts is where this firm works.

This article is provided for general informational purposes and does not constitute legal advice or create an attorney-client relationship. Coverage rules, agency guidance, and case law change, and application depends on specific facts and jurisdiction.

Authorities: Reuters and ABC News/AP reporting on former President Biden’s May 2025 diagnosis and PSA testing history; U.S. Preventive Services Task Force, Screening for Prostate Cancer recommendation statement (2018) and USPSTF Grade Definitions; Public Health Service Act § 2713, 42 U.S.C. § 300gg-13; implementing preventive-services regulations, including 29 C.F.R. § 2590.715-2713, 45 C.F.R. § 147.130, and 26 C.F.R. § 54.9815-2713; Kennedy v. Braidwood Management, Inc., No. 24-316, 606 U.S. ___ (2025); Braidwood Management, Inc. v. Becerra, 104 F.4th 930 (5th Cir. 2024), where relevant to continuing remand issues; Social Security Act § 1861(oo), 42 U.S.C. § 1395x(oo); 42 C.F.R. § 410.39; CMS National Coverage Determination 210.1, Prostate Cancer Screening Tests; CMS National Coverage Determination 190.31, Prostate Specific Antigen; Medicare.gov, Prostate Cancer Screenings; HCFA Ruling 86-1 and CMS Medicare Program Integrity Manual, Pub. 100-08, Ch. 8, on statistical sampling and extrapolated overpayments; 31 U.S.C. § 3729(b)(1); United States ex rel. Schutte v. SuperValu Inc., 598 U.S. 739 (2023); American Cancer Society, Insurance Coverage for Prostate Cancer Screening, for general background on state-law variation.